Sangamo Announces ASGCT 2024

Uncategorized

Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results

Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total. Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in HLA A2 mismatched kidney transplantation. Unveiled Nav1.7 target to treat chronic neuropathic pain as